{"id":77568,"date":"2026-08-31T20:58:47","date_gmt":"2026-08-31T12:58:47","guid":{"rendered":"https:\/\/flcube.com\/?p=77568"},"modified":"2026-08-31T20:58:48","modified_gmt":"2026-08-31T12:58:48","slug":"mabwell-licenses-synusights-sst001-pet-tracer-for-%ce%b1-synuclein-imaging-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77568","title":{"rendered":"Mabwell Licenses SynuSight&#8217;s SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688062:SHA\">SHA: 688062<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2493:HKG\">HKG: 2493<\/a>) announced it has entered into a license agreement with <strong>SynuSight BioTech<\/strong> for the innovative PET tracer <strong>SST001<\/strong>, a proprietary molecular imaging agent targeting \u03b1\u2011synuclein (\u03b1\u2011syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of <strong>Parkinson&#8217;s disease (PD)<\/strong> and <strong>multiple system atrophy (MSA)<\/strong>, extending the antibody specialist&#8217;s reach into neurological molecular imaging.<\/p>\n\n\n\n<h2 id=\"h-deal-structure\" class=\"wp-block-heading\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Licensee<\/td><td><strong>Mabwell<\/strong> (SHA: 688062; HKG: 2493)<\/td><\/tr><tr><td>Licensor<\/td><td><strong>SynuSight BioTech<\/strong><\/td><\/tr><tr><td>Asset<\/td><td><strong>SST001<\/strong>, PET molecular tracer targeting \u03b1\u2011synuclein<\/td><\/tr><tr><td>Territory<\/td><td>Greater China (Hong Kong, Macau, and Taiwan)<\/td><\/tr><tr><td>Exclusivity<\/td><td>Exclusive license<\/td><\/tr><tr><td>Date<\/td><td>31 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-financial-terms\" class=\"wp-block-heading\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount \/ Rate<\/th><\/tr><\/thead><tbody><tr><td>Upfront Payment<\/td><td>RMB 20 million<\/td><\/tr><tr><td>Milestone \u2013 Phase 3 Initiation<\/td><td>RMB 8 million<\/td><\/tr><tr><td>Milestone \u2013 Marketing Authorization<\/td><td>RMB 12 million<\/td><\/tr><tr><td>Royalties<\/td><td>4.3% of net sales following first commercial sale<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-sst001\" class=\"wp-block-heading\">Asset Profile \u2013 SST001<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> Proprietary PET molecular tracer<\/li>\n\n\n\n<li><strong>Target:<\/strong> \u03b1\u2011synuclein (\u03b1\u2011syn), the pathological protein hallmark of synucleinopathies<\/li>\n\n\n\n<li><strong>Intended Utility:<\/strong> Clinical trials to evaluate use in diagnosis and treatment of Parkinson&#8217;s disease and multiple system atrophy<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Direct imaging of \u03b1\u2011synuclein pathology addresses a critical gap \u2014 current PD diagnostics rely largely on clinical assessment and dopaminergic imaging rather than disease\u2011specific biomarkers<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Planned clinical trial program to be conducted by the parties under the agreement<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction pairs <strong>SynuSight<\/strong>&#8216;s radiotracer discovery capability with <strong>Mabwell<\/strong>&#8216;s clinical development and commercialization infrastructure in Greater China. For SynuSight, the deal converts an early\u2011stage neuroscience asset into near\u2011term cash and milestone economics; for Mabwell, it diversifies the portfolio beyond monoclonal antibodies into the fast\u2011emerging neurodegenerative diagnostics space.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neuro Diagnostics Frontier:<\/strong> \u03b1\u2011synuclein PET imaging is among the most sought\u2011after tools in neurology, with no approved tracer currently able to directly visualize synuclein pathology in living patients<\/li>\n\n\n\n<li><strong>Strategic Diversification:<\/strong> The license expands Mabwell&#8217;s pipeline adjacency into CNS imaging and theranostics while preserving its antibody core<\/li>\n\n\n\n<li><strong>Regional Focus:<\/strong> Greater China exclusivity aligns with rising demand for early and differential diagnosis of Parkinsonian syndromes in an aging population<\/li>\n\n\n\n<li><strong>Deal Economics:<\/strong> Modest upfront with milestone and royalty structure reflects early\u2011stage risk sharing, while preserving upside if SST001 validates in pivotal trials<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding the development, regulatory progress, and commercialization of SST001 under the Mabwell\u2013SynuSight agreement. Actual results may differ materially due to risks inherent in drug development, regulatory review, and competitive dynamics. Readers should not place undue reliance on such statements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026083000138_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026083000138_c.\"><\/object><a id=\"wp-block-file--media-261874db-c26e-4664-b2d5-ec5f8a017fc9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026083000138_c.pdf\">2026083000138_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026083000138_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-261874db-c26e-4664-b2d5-ec5f8a017fc9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4705,118,1129,4530],"class_list":["post-77568","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2493","tag-mabwell-bioscience","tag-sha-688062","tag-synusight-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Licenses SynuSight&#039;s SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a license agreement with SynuSight BioTech for the innovative PET tracer SST001, a proprietary molecular imaging agent targeting \u03b1\u2011synuclein (\u03b1\u2011syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of Parkinson&#039;s disease (PD) and multiple system atrophy (MSA), extending the antibody specialist&#039;s reach into neurological molecular imaging.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77568\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Licenses SynuSight&#039;s SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a license agreement with SynuSight BioTech for the innovative PET tracer SST001, a proprietary molecular imaging agent targeting \u03b1\u2011synuclein (\u03b1\u2011syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of Parkinson&#039;s disease (PD) and multiple system atrophy (MSA), extending the antibody specialist&#039;s reach into neurological molecular imaging.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77568\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T12:58:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-31T12:58:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77568#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77568\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Licenses SynuSight&#8217;s SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China\",\"datePublished\":\"2026-08-31T12:58:47+00:00\",\"dateModified\":\"2026-08-31T12:58:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77568\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2493\",\"Mabwell Bioscience\",\"SHA: 688062\",\"SynuSight Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77568#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77568\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77568\",\"name\":\"Mabwell Licenses SynuSight's SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-31T12:58:47+00:00\",\"dateModified\":\"2026-08-31T12:58:48+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a license agreement with SynuSight BioTech for the innovative PET tracer SST001, a proprietary molecular imaging agent targeting \u03b1\u2011synuclein (\u03b1\u2011syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of Parkinson's disease (PD) and multiple system atrophy (MSA), extending the antibody specialist's reach into neurological molecular imaging.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77568#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77568\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77568#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Licenses SynuSight&#8217;s SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Licenses SynuSight's SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a license agreement with SynuSight BioTech for the innovative PET tracer SST001, a proprietary molecular imaging agent targeting \u03b1\u2011synuclein (\u03b1\u2011syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of Parkinson's disease (PD) and multiple system atrophy (MSA), extending the antibody specialist's reach into neurological molecular imaging.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77568","og_locale":"en_US","og_type":"article","og_title":"Mabwell Licenses SynuSight's SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a license agreement with SynuSight BioTech for the innovative PET tracer SST001, a proprietary molecular imaging agent targeting \u03b1\u2011synuclein (\u03b1\u2011syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of Parkinson's disease (PD) and multiple system atrophy (MSA), extending the antibody specialist's reach into neurological molecular imaging.","og_url":"https:\/\/flcube.com\/?p=77568","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-31T12:58:47+00:00","article_modified_time":"2026-08-31T12:58:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77568#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77568"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Licenses SynuSight&#8217;s SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China","datePublished":"2026-08-31T12:58:47+00:00","dateModified":"2026-08-31T12:58:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77568"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2493","Mabwell Bioscience","SHA: 688062","SynuSight Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77568#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77568","url":"https:\/\/flcube.com\/?p=77568","name":"Mabwell Licenses SynuSight's SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-31T12:58:47+00:00","dateModified":"2026-08-31T12:58:48+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a license agreement with SynuSight BioTech for the innovative PET tracer SST001, a proprietary molecular imaging agent targeting \u03b1\u2011synuclein (\u03b1\u2011syn). Under the deal, Mabwell gains exclusive rights in Greater China to develop the tracer for the diagnosis and treatment of Parkinson's disease (PD) and multiple system atrophy (MSA), extending the antibody specialist's reach into neurological molecular imaging.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77568#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77568"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77568#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Licenses SynuSight&#8217;s SST001 PET Tracer for \u03b1\u2011Synuclein Imaging in Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77568"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77568\/revisions"}],"predecessor-version":[{"id":77570,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77568\/revisions\/77570"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}